<!DOCTYPE html>
<!--[if lt IE 9]><html class="no-js lt-ie9" lang="en" dir="ltr"><![endif]-->
<!--[if gt IE 8]><!-->
<html class="no-js" lang="en" dir="ltr">
<!--<![endif]-->

<head>
	<meta charset="utf-8">
	<!-- Web Experience Toolkit (WET) / Boîte à outils de l'expérience Web (BOEW) wet-boew.github.io/wet-boew/License-en.html / wet-boew.github.io/wet-boew/Licence-fr.html -->
	<title>COVID-19 Vaccine and drug progress tracker - Canada.ca</title>
	<meta content="width=device-width,initial-scale=1" name="viewport">
	<!-- Meta data -->
	<!-- Meta data-->
	<!-- Load closure template scripts -->
	<script type="text/javascript"
		src="https://www.canada.ca/etc/designs/canada/cdts/gcweb/v4_0_30/cdts/compiled/soyutils.js"></script>
	<script type="text/javascript"
		src="https://www.canada.ca/etc/designs/canada/cdts/gcweb/v4_0_30/cdts/compiled/wet-en.js"></script>
	<link href="https://test.canada.ca/covid-19-guidance/proto/css/alpha-beta-banner.css" rel="stylesheet">
	<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.8.1/css/all.css"
		integrity="sha384-50oBUHEmvpQ+1lW4y57PTFmhCaXp0ML5d60M1M7uH2+nqUivzIebhndOJK28anvf" crossorigin="anonymous" />

	<!-- Write closure template -->
	<script type="text/javascript">
		document.write(wet.builder.refTop({
		}));
	</script>
</head>

<body vocab="http://schema.org/" typeof="WebPage">
	<div id="def-top">
	</div>
	<!-- Write closure template -->
	<script type="text/javascript">
		var defTop = document.getElementById("def-top");
		defTop.outerHTML = wet.builder.top({
			lngLinks: [{
				lang: "fr",
				href: "travel-advice-fr.html",
				text: "Français"
			}],
			breadcrumbs: [{
				title: "Home",
				href: "https://www.canada.ca/en.html"
			}, {
				title: "Health",
				href: "https://www.canada.ca/en/services/health.html"
			}, {
				title: "Diseases and conditions",
				href: "https://www.canada.ca/en/public-health/services/diseases.html"
			}, {
				title: "Coronavirus (COVID-19)",
				href: "landing.html"
			}],
			search: true,
			siteMenu: true,
			showPreContent: true
		});
	</script>
	<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.8.1/css/all.css"
		integrity="sha384-50oBUHEmvpQ+1lW4y57PTFmhCaXp0ML5d60M1M7uH2+nqUivzIebhndOJK28anvf" crossorigin="anonymous" />

	<main role="main" property="mainContentOfPage" class="container">

		<h1 property="name" id="wb-cont" dir="ltr">Drugs and vaccines for COVID-19: Progress tracker <br> </h1>

		<div class="row">

			<div class="col-md-6 pull-right mrgn-tp-lg panel panel-default">
				<p class="mrgn-tp-md"><span class="text-info h2">77%</span> of Canadians report they are likely to get a
					<span class="no-break"></span>COVID-19 vaccination when it's available.</p>
				<p><strong>Source:</strong> <a
						href="https://www150.statcan.gc.ca/n1/pub/45-28-0001/2020001/article/00073-eng.htm">Statistics
						Canada - Canadians' willingness to get a COVID-19 vaccine</a></p>
			</div>
			<div class="col-md-6 pull-left">
				<h2>On this page</h2>
				<ul>
					<li><a href="#a1">Securing potential vaccines and supplies</a></li>
					<li><a href="#a2">Vaccine progress in Canada</a></li>
					<li><a href="#a3">Drug and treatment progress in Canada</a></li>
					<li><a href="#a4">Government funding for vaccine and treatment research</a></li>
					<li><a href="#a5">Vaccines are safe to use and crucial to protecting Canadians</a></li>
				</ul>
			</div>

		</div>

		<section class="well well-sm brdr-0 mrgn-bttm-0">
			<div class="container-fluid mrgn-tp-sm mrgn-bttm-sm">
				<h2 id="a1" class="mrgn-tp-0">Securing potential vaccines and supplies</h2>
				<p>The Government of Canada is securing millions of doses of potential vaccine candidates. All potential
					vaccines will require Health Canada authorization prior to being used to vaccinate Canadians.
					Clinical human trials in phases help ensure that potential COVID-19 vaccines are safe and effective.
				</p>

				<div class="row mrgn-bttm-sm">
					<div class="col-xs-12 mrgn-tp-sm">

						<h3 class="pull-left mrgn-tp-0 h3 text-info" id="agreements">Agreements for potential vaccines
							and human trial status</h3>
						<div class="clearfix"></div>

						<table class="table table-striped table-hover table-responsive small">
							<thead>
								<tr>
									<th scope="col">Supplier</th>
									<th scope="col">Doses</th>
									<th scope="col">Human trials</th>
									<th scope="col">Vaccine at Clinicaltrials.gov</th>
									<th scope="col">Authorization in Canada</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>AstraZeneca</td>
									<td><a
											href="https://pm.gc.ca/en/news/news-releases/2020/09/25/new-agreements-secure-additional-vaccine-candidates-covid-19">up
											to 20 million</a></td>
									<td>Phases:<span class="label label-info">3</span></td>
									<td><a href="https://clinicaltrials.gov/ct2/results?cond=&term=AZD1222">AZD1222</a>
									</td>
									<td><span class="label label-default">None</span></td>
								</tr>
								<tr>
									<td>Johnson and Johnson</td>
									<td><a
											href="https://pm.gc.ca/en/news/news-releases/2020/08/31/new-measures-ensure-supply-future-vaccines-and-therapies-against">up
											to 38 million</a></td>
									<td>Phases:<span class="label label-info">1</span><span
											class="label label-info">2</span><span class="label label-info">3</span>
									</td>
									<td><a
											href="https://clinicaltrials.gov/ct2/results?cond=&term=Ad26.COV2.S">Ad26.COV2.S</a>
									</td>
									<td><span class="label label-default">None</span></td>
								</tr>
								<tr>
									<td>Medicago <span class="fab fa-canadian-maple-leaf" style="color:#af3c43;"></span>
									</td>
									<td><a
											href="https://pm.gc.ca/en/news/news-releases/2020/10/23/prime-minister-announces-funding-advance-development-canadian-covid">Up
											to 76 million</a></td>
									<td>Phases:<span class="label label-info">1</span></td>
									<td><a
											href="https://clinicaltrials.gov/ct2/results?cond=&term=Recombinant+Coronavirus-Like+Particle&cntry=CA&state=&city=&dist=">Coronavirus-Like
											Particle</a></td>
									<td><span class="label label-default">None</span></td>
								</tr>
								<tr>
									<td>Moderna</td>
									<td><a
											href="https://www.canada.ca/en/innovation-science-economic-development/news/2020/08/government-of-canada-announces-major-steps-in-treating-and-preventing-covid-19-through-vaccines-and-therapies.html">up
											to 56 million</a></td>
									<td>Phases:<span class="label label-info">1</span><span
											class="label label-info">2</span><span class="label label-info">3</span>
									</td>
									<td><a
											href="https://clinicaltrials.gov/ct2/results?cond=&term=mRNA-1273">mRNA-1273</a>
									</td>
									<td><span class="label label-default">None</span></td>
								</tr>
								<tr>
									<td>Novavax</td>
									<td><a
											href="https://pm.gc.ca/en/news/news-releases/2020/08/31/new-measures-ensure-supply-future-vaccines-and-therapies-against">up
											to 76 million</a></td>
									<td>Phases:<span class="label label-info">1</span><span
											class="label label-info">2</span></td>
									<td><a
											href="https://clinicaltrials.gov/ct2/results?cond=&term=NVX-CoV2373">NVX-CoV2373</a>
									</td>
									<td><span class="label label-default">None</span></td>
								</tr>
								<tr>
									<td>Pfizer</td>
									<td><a
											href="https://www.canada.ca/en/innovation-science-economic-development/news/2020/08/government-of-canada-announces-major-steps-in-treating-and-preventing-covid-19-through-vaccines-and-therapies.html">minimum
											of 20 million</a></td>
									<td>Phases:<span class="label label-info">1</span><span
											class="label label-info">2</span><span class="label label-info">3</span>
									</td>
									<td><a href="https://clinicaltrials.gov/ct2/results?cond=&term=BNT162">BNT162</a>
									</td>
									<td><span class="label label-default">None</span></td>
								</tr>
								<tr>
									<td>Sanofi and GlaxoSmithKline</td>
									<td><a
											href="https://www.canada.ca/en/public-services-procurement/news/2020/09/government-of-canada-signs-new-agreements-to-secure-additional-vaccine-candidate-and-treatment-for-covid-19.html">Up
											to 72 million</a></td>
									<td>Phases:<span class="label label-info">1</span><span
											class="label label-info">2</span></td>
									<td><a href="https://clinicaltrials.gov/ct2/show/NCT04537208">Protein subunit
											vaccine and adjuvant</a></td>
									<td><span class="label label-default">None</span></td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>

				<h3 class="text-info">Planning for manufacturing and immunization</h3>
				<p>Plans and purchases are being made to efficiently, effectively and equitably produce, distribute and
					administer an eventual COVID-19 vaccine. These include: </p>
				<ul>
					<li><a
							href="https://nrc.canada.ca/en/research-development/research-collaboration/increasing-biomanufacturing-capacity">Accelerate
							production and testing of vaccine candidates</a> by the National Research Council </li>
					<li>Agreements to purchase syringes, alcohol swabs and other immunization supplies</li>
					<li>Funding and agreements for final manufacturing and packing stages of vaccine production in
						Canada</li>
					<li><a
							href="https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/research-priorities-covid-19-vaccines.html#toc8">Assess
							feasibility and equity</a> of options for storage and handling and administration </li>
				</ul>
				<p>Supported by: <a href="https://www.tpsgc-pwgsc.gc.ca/comm/index-eng.html">Public Services and
						Procurement Canada</a>, <a href="https://www.ic.gc.ca/eic/site/icgc.nsf/eng/home">Innovation,
						Science and Economic Development</a>, <a
						href="https://nrc.canada.ca/en/corporate/covid-19-vaccine-task-force">the COVID-19 Vaccine Task
						Force </a>and, <a href="https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/hn01780.html">the
						COVID-19 Therapeutics Task Force</a>. </p>
			</div>
		</section>

		<section class="well-sm">
			<div class="container-fluid mrgn-tp-sm mrgn-bttm-sm">
				<h2 id="a2">Vaccine progress in Canada</h2>
				<p>All drugs, including vaccines, are evaluated by Health Canada's scientific reviewers to assess the
					potential benefits and risks. Products must meet Health Canada's requirements for safety, efficacy
					and quality before they can be used in Canada. Human trials for some vaccines are taking place in
					Canada.</p>
				<h3 class="text-info" id="confirm-registration">Vaccines authorized for use in Canada:none </h3>
				<p>Health Canada is closely tracking all potential vaccines in development. Authorization processes may
					begin during clinical trials in other countris, as well as in Canada. </p>

				<h3 class="text-info" id="confirm-registration">Vaccine clinical trials with Canadian participants</h3>
				<p>Want to participate? Use the Clinicaltrials.gov link to find out if a trial is recruiting in your
					area. </p>
				<div class="table-responsive">
					<table class="table table-striped table-hover table-responsive small">
						<thead>
							<tr>
								<th scope="col">Trial Name /Protocol #/control #</th>
								<th scope="col">Title</th>
								<th scope="col">Interventions</th>
								<th scope="col">Authorization holder</th>
								<th scope="col">Authorization date</th>
								<th scope="col">Clinicaltrials.gov Link</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>COBRA<br>
									(Control # 238868)</td>
								<td>A randomized, double-blind, placebo-controlled phase 3 study: Efficacy and safety of
									recombinant BCG VPM1002 in reducing SARS-CoV-2 infection rate and COVID-19 severity
								</td>
								<td>Vaccine: Recombinant<br>
									Mycobacterium bovis<br>
									BCGΔureC::hly</td>
								<td>Princess Margaret Cancer Centre</td>
								<td>2020-05-08</td>
								<td><a href="https://clinicaltrials.gov/ct2/show/NCT04439045">#NCT04439045</a></td>
							</tr>
							<tr>
								<td>CP-PRO-CoVLP-019<br>
									(Control # 240922)</td>
								<td>A randomized, partially-blinded, dose-ranging phase 1 study to assess the safety,
									tolerability, and immunogenicity of a recombinant coronavirus-Like particle COVID-19
									vaccine in adults 18-55 Years of age</td>
								<td>Vaccine: Coronavirus-like Particle (CoVLP) COVID-19 Vaccine</td>
								<td>Medicago Inc.</td>
								<td>2020-07-09</td>
								<td><a href="https://clinicaltrials.gov/ct2/show/NCT04450004">#NCT04450004</a></td>
							</tr>
							<tr>
								<td>IC.8 (Control # 240586) Filed under the Clinical Trial Interim Order</td>
								<td>COV-IMMUNO - A Randomized, Phase III Trial of Immunization with IMM-101 versus
									Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections
									in Cancer Patients at Increased Risk of Exposure</td>
								<td>Vaccine: IMM-101</td>
								<td>Canadian Cancer Trials Group, Cancer Research Institute, Queen's University</td>
								<td>2020-06-24</td>
								<td><a
										href="https://clinicaltrials.gov/ct2/show/NCT04442048?term=Canadian+Cancer+Trials+Group&amp;cond=COVID-19&amp;draw=2&amp;rank=1">NCT04442048</a>
								</td>
							</tr>

						</tbody>
					</table>
				</div>

				<p>Canada's National Advisory Committee on Immunization (NACI) is providing rapid guidance on clinical
					trial research priorities for COVID-19 vaccine candidates.</p>
				<ul>
					<li><a
							href="https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci.html">National
							Advisory Committee on Immunization</a></li>
				</ul>
				<p>Supported by: <a
						href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/conducting-clinical-trial.html">Health
						Canada - Conducting COVID-19 clinical trials</a></p>

			</div>
		</section>
		<section class="well-sm">
			<div class="container-fluid mrgn-tp-sm mrgn-bttm-sm">
				<h2 id="a3">Drugs and treatment progress in Canada</h2>
				<p>There are many potential drugs being investigated in Canada and around the world for use against
					COVID-19. Drugs must meet the regulatory requirements for safety, efficacy and quality before they
					are authorized for use in Canada. </p>
				<h3 class="pull-left mrgn-tp-0 mrgn-lft-sm text-info" id="drugs-approved">Drugs authorized for the
					treatment of COVID-19</h3>
				<div class="clearfix"></div>
				<ul>
					<li><a
							href="https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00669">Veklury
							- Remdesivir solution for injection</a></li>
				</ul>

				<h3 class="text-info">Clinical trials of drugs in Canada </h2>
					<p>Potential COVID-19 drugs currently being investigated in authorized Canadian clinical trials
						include:</p>
					<ul>
						<li>antiviral drugs</li>
						<li>anti-malarial drugs</li>
						<li>monoclonal antibodies and other drugs that address inflammation</li>
						<li><a href="https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72957a-eng.php">convalescent
								plasma</a> collected from patients who have recovered from COVID-19</li>
						<li>medical gases</li>
					</ul>
					<p>See the complete <a href="./drugs-vaccines-authorized-clinical-trials.html">list of authorized
							COVID-19 clinical trials</a></p>
					<p>Supported by: <a
							href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization.html">Health
							Canada - Drug and vaccine authorizations for COVID-19</a></p>

			</div>
		</section>

		<section class="well well-sm brdr-0 mrgn-bttm-0">
			<div class="container-fluid mrgn-tp-sm mrgn-bttm-sm">
				<h2 id="a4" class="mrgn-tp-0">Government funding for vaccine and treatment research</h3>
					<p>Funding from Innovation Canada for the most promising options for safe, effective vaccines is
						being made available to vaccine and bio-manufacturing applications from domestic candidates
						reviewed by the COVID-19 Task Force.</p>


					<h3 class="text-info" id="confirm-registration">Funding early stage vaccines in Canada</h3>
					<div class="table-responsive">
						<table class="table table-striped table-hover table-responsive small">
							<thead>
								<tr>
									<th scope="col">Vaccine developer</th>
									<th scope="col">Vaccine</th>
									<th scope="col">Funding announcement</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>IMV Inc.</td>
									<td>BNT162</td>
									<td><a
											href="https://www.canada.ca/en/innovation-science-economic-development/news/2020/08/government-of-canada-announces-major-steps-in-treating-and-preventing-covid-19-through-vaccines-and-therapies.html">Multiple
											sources</a></td>
								</tr>	
								<tr>
									<td>Medicago</td>
									<td>Coronavirus-like particle</td>
									<td><a
											href="https://pm.gc.ca/en/news/news-releases/2020/10/23/prime-minister-announces-funding-advance-development-canadian-covid">Strategic Innovation Fund</a></td>
								</tr>							
								<tr>
									<td>Precision NanoSystems Inc.</td>
									<td>mRNA candidate</td>
									<td><a
											href="https://pm.gc.ca/en/news/news-releases/2020/10/23/prime-minister-announces-funding-advance-development-canadian-covid">Strategic Innovation Fund</a></td>
								</tr>								<tr>
									<td>Variation Biotechnologies Inc.</a></td>
									<td>VBI-2900</td>
									<td><a
											href="https://www.canada.ca/en/innovation-science-economic-development/news/2020/08/government-of-canada-announces-major-steps-in-treating-and-preventing-covid-19-through-vaccines-and-therapies.html">Strategic
											Innovation Fund</sa>
									</td>
								</tr>
								<tr>
									<td>VIDO-Intervac</a></td>
									<td>Not named</td>
									<td><a
											href="https://pm.gc.ca/en/news/news-releases/2020/04/23/prime-minister-announces-new-support-covid-19-medical-research-and">Multiple
											sources</sa>
									</td>
								</tr>

							</tbody>
						</table>
					</div>


					<div class="row mrgn-bttm-md">
						<div class="col-xs-12">
							<h3 class="pull-left mrgn-tp-0 mrgn-lft-sm h3 text-info" id="confirm-registration">COVID-19
								basic vaccine research funding</h3>
							<div class="clearfix"></div>
							<div class="table-responsive">

								<p>The national medical research strategy to fight COVID-19 includes support for basic
									genetic and vaccine research and immunization strategies. </p>
								<table class="table table-striped table-hover table-responsive small">
									<thead>
										<tr>
											<th scope="col">Research activity</th>
											<th scope="col">Announcement date</th>
											<th scope="col">Vaccine projects</th>
											<th scope="col">Funding</th>
										</tr>
									</thead>
									<tbody>
										<tr>
											<td>Canadian Institutes of Health Research(CIHR)</td>
											<td><a href="https://cihr-irsc.gc.ca/e/51908.html">February 2020
													competition</a></td>
											<td><a
													href="https://webapps.cihr-irsc.gc.ca/decisions/p/main.html?lang=en#fq={!tag=competitioncd}competitioncd%3A202002OV5&sort=namesort%20asc&start=0&rows=20">6
													projects</a></td>
											<td><span class="label label-success">$5.1 million</span></td>
										</tr>
										<tr>
											<td>Canadian Institutes of Health Research(CIHR)</td>
											<td><a href="https://cihr-irsc.gc.ca/e/52013.html">May 2020 competition</a>
											</td>
											<td><a
													href="https://webapps.cihr-irsc.gc.ca/decisions/p/main.html?lang=en#fq={!tag=competitioncd}competitioncd%3A202005VR1&sort=namesort%20asc&start=0&rows=20">8
													projects</a></td>
											<td><span class="label label-success">$11.7 million</span></td>
										</tr>
										<tr>
											<td>Canadian Immunization Research Network</td>
											<td>April 2020</td>
											<td><a
													href="https://pm.gc.ca/en/news/news-releases/2020/04/23/prime-minister-announces-new-support-covid-19-medical-research-and">trials
													and monitoring</a></td>
											<td><span class="label label-success">$15.3 million</span></td>
										</tr>
									</tbody>
								</table>

								<h3 class="pull-left mrgn-tp-0 mrgn-lft-sm h3 text-info" id="drug">COVID-19 drug and
									therapeutic research funding</h3>
								<table class="table table-striped table-hover table-responsive small">
									<thead>
										<tr>
											<th scope="col">Research activity</th>
											<th scope="col">Announcement date</th>
											<th scope="col">Projects</th>
											<th scope="col">Funding</th>
										</tr>
									</thead>
									<tbody>
										<tr>
											<td>Canadian Institutes of Health Research(CIHR)</td>
											<td><a href="https://cihr-irsc.gc.ca/e/51908.html">February 2020 -
													Therapeutics</a></td>
											<td>18 projects</td>
											<td><span class="label label-success">$11.5 million</span></td>
										</tr>
										<tr>
											<td>Canadian Institutes of Health Research(CIHR)</td>
											<td><a href="https://cihr-irsc.gc.ca/e/52013.html">May 2020 -
													Therapeutics</a></td>
											<td>30 projects</td>
											<td><span class="label label-success">$35.1 million</span></td>
										</tr>
										</tr>
										<tr>
											<td>AbCellera</td>
											<td>May 3, 2020</td>
											<td><a
													href="https://www.canada.ca/en/innovation-science-economic-development/news/2020/05/minister-bains-announces-investment-in-antibody-discovery-technology-to-help-treat-covid-19.html">Antibody
													drugs</a></td>
											<td><span class="label label-success">$175.6 million</span></td>
										</tr>
										</tr>
									</tbody>
								</table>
							</div>
						</div>
						<p>Supported by: <a href="https://www.ic.gc.ca/eic/site/icgc.nsf/eng/home">Innovation, Science
								and Economic Development</a>, <a href="https://cihr-irsc.gc.ca/e/193.htmland"> Canadian
								Institutes of Health Research (CIHR)</a> ,<a
								href="https://nrc.canada.ca/en/corporate/covid-19-vaccine-task-force">the COVID-19
								Vaccine Task Force </a> and, <a
								href="https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/hn01780.html">the COVID-19
								Therapeutics Task Force</a>.</p>
					</div>
			</div>
		</section>

		<section class="well-sm">
			<div class="container-fluid mrgn-tp-sm mrgn-bttm-sm">
				<h2 id="a5">Vaccines and drugs are safe to use and crucial to protecting Canadians</h2>
				<p>The Government of Canada has strict regulations and testing requirements to ensure that authorized
					vaccines and drugs are safe to use. We continue to monitor and assess the safety and effectiveness
					of a product once it is on the Canadian market
				</p>

				<ul>
					<li><a
							href="https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/activities/fact-sheets/regulation-vaccines-human-canada.html">How
							the Government of Canada ensures vaccines are safe for use</a></li>
					<li><a href="http://www.icmra.info/drupal/strategicinitiatives/vaccines/statement_general_public">International
							statement about confidence in vaccines</a></li>
				</ul>
				<h3>Working with international partners to ensure vaccines are safe and widely adopted</h3>
				<p>Canada is working with <a
						href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/engaging-international-partners.html">international
						partners</a> on a coordinated and well-aligned approach to this global pandemic. This ensures
					that health products are safe, effective and quickly available to Canadians. Collaboration also
					helps advance the development of diagnostics, treatments and vaccines that will save lives and
					protect the health and safety of people everywhere. </p>
				<ul>
					<li>Canada has committed to <a
							href="https://www.canada.ca/en/global-affairs/news/2020/05/minister-gould-announces-funding-for-global-vaccinations.html">funding
							global vaccinations for COVID-19</a></li>
				</ul>
			</div>
			</div>

			<div id="def-preFooter">
			</div>
			<!-- Write closure template -->
			<script type="text/javascript">
				var defPreFooter = document.getElementById("def-preFooter");
				defPreFooter.outerHTML = wet.builder.preFooter({
					dateModified: "2020-03-13",
					showPostContent: true,
					showFeedback: true,
					showShare: true
				});
			</script>
	</main>
	<div id="def-footer">

	</div>
	<!-- Write closure template -->
	<script type="text/javascript">
		var defFooter = document.getElementById("def-footer");
		defFooter.outerHTML = wet.builder.footer({
			showFooter: true,
			showFeatures: true
		});
	</script>
	<!-- Write closure template -->
	<script type="text/javascript">
		document.write(wet.builder.refFooter({
		}));
	</script>
	<script src="https://test.canada.ca/covid-19-guidance/proto/js/contact-link-swap.js"></script>
	<script src="https://test.canada.ca/covid-19-guidance/proto/js/alpha-banner.js"></script>
</body>

</html>